Reply to Is progesterone a neutral or protective factor for breast cancer?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A human breast atlas integrating single-cell proteomics and transcriptomics.Developmental cell · 2022
   Article
2. Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients.Cancer management and research · 2021
   Article
3. Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.Oncotarget · 2018
   Article
4. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.Bioengineered · 2017
   Article

Corrections and comments

• Comment on
  Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.2013
• Comment on
  Is progesterone a neutral or protective factor for breast cancer?2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as